Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study
Journal article published in 2020 by
Janice M. Mehnert 
,
Emily Bergsland,
Bert H. O’Neil,
Armando Santoro ,
Jan H. M. Schellens,
Roger B. Cohen,
Toshihiko Doi,
Patrick A. Ott,
Michael J. Pishvaian ,
Igor Puzanov,
Kyaw L. Aung ,
Chiun Hsu ,
Christophe Le Tourneau,
Antoine Hollebecque,
Elena Élez
and other authors.
,
Emily Bergsland,
Bert H. O’Neil,
Armando Santoro ,
Jan H. M. Schellens,
Roger B. Cohen,
Toshihiko Doi,
Patrick A. Ott,
Michael J. Pishvaian ,
Igor Puzanov,
Kyaw L. Aung ,
Chiun Hsu ,
Christophe Le Tourneau,
Antoine Hollebecque,
Elena Élez
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 